Onyx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ONXX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Onyx Pharmaceuticals (NASDAQ:ONXX)

Onyx Pharmaceuticals logoOnyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. The Company is developing therapies that target the molecular mechanisms that cause cancer. The Company has built two franchise platforms: one in kinase inhibition and one in proteasome inhibition. In its kinase inhibitor franchise, its product, Nexavar (sorafenib) tablets is approved for unresectable liver cancer and advanced kidney cancer. unresectable liver cancer and advanced kidney cancer. With its development and marketing partner Bayer HealthCare Pharmaceuticals Inc., or Bayer, the Company shares equally in the profits and losses of Nexavar worldwide except Japan. A kinase inhibitor, regorafenib, is an investigational agent that has already demonstrated positive Phase 3 survival data in metastatic colorectal cancer, and is being evaluated in a Phase 3 study in gastrointestinal stromal tumors (GIST).

Receive ONXX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ONXX
CUSIP68339910
WebN/A
Phone+1-650-2660000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

Onyx Pharmaceuticals (NASDAQ:ONXX) Frequently Asked Questions

What is Onyx Pharmaceuticals' stock symbol?

Onyx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ONXX."

Who are some of Onyx Pharmaceuticals' key competitors?

How do I buy Onyx Pharmaceuticals stock?

Shares of Onyx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Onyx Pharmaceuticals?

Onyx Pharmaceuticals' mailing address is 249 E Grand Ave, SOUTH SAN FRANCISCO, CA 94080-4804, United States. The biopharmaceutical company can be reached via phone at +1-650-2660000.


MarketBeat Community Rating for Onyx Pharmaceuticals (ONXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  438
MarketBeat's community ratings are surveys of what our community members think about Onyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Onyx Pharmaceuticals (NASDAQ:ONXX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Onyx Pharmaceuticals (NASDAQ:ONXX) Earnings History and Estimates Chart

Earnings by Quarter for Onyx Pharmaceuticals (NASDAQ:ONXX)

Onyx Pharmaceuticals (NASDAQ ONXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2013Q2 2013($0.42)($0.40)$151.73 million$153.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.47)($0.19)$134.36 million$145.50 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.76)($0.36)$113.17 million$127.90 millionViewN/AView Earnings Details
11/1/2012Q312($0.95)($0.79)$80.02 million$89.51 millionViewN/AView Earnings Details
8/1/2012($0.69)($0.68)ViewN/AView Earnings Details
5/2/2012($0.60)($0.68)ViewN/AView Earnings Details
2/22/2012$1.61$1.50ViewN/AView Earnings Details
11/2/2011($0.27)($0.31)ViewN/AView Earnings Details
8/3/2011($0.17)($0.43)ViewN/AView Earnings Details
5/4/2011($0.13)($0.23)ViewN/AView Earnings Details
2/23/2011($0.02)($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Onyx Pharmaceuticals (NASDAQ:ONXX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Onyx Pharmaceuticals (NASDAQ:ONXX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Onyx Pharmaceuticals (NASDAQ:ONXX)

Onyx Pharmaceuticals (NASDAQ ONXX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2013Helen TorleyEVPSell9,311$126.89$1,181,472.79View SEC Filing  
8/8/2013Matthew FustCFOSell2,492$128.21$319,499.32View SEC Filing  
8/7/2013Suzanne ShemaEVPSell4,052$131.86$534,296.72View SEC Filing  
8/6/2013Kaye Foster-CheekSVPSell8,878$132.81$1,179,087.18View SEC Filing  
7/30/2013Corinne H NevinnyDirectorSell1,500$131.26$196,890.00View SEC Filing  
7/26/2013Lopez Antonio J GrilloDirectorSell2,000$130.50$261,000.00View SEC Filing  
7/26/2013Matthew K FustCFOSell6,043$130.50$788,611.50View SEC Filing  
7/8/2013Suzanne M ShemaEVPSell4,052$135.76$550,099.52View SEC Filing  
7/2/2013Matthew K FustCFOSell1,551$132.80$205,972.80View SEC Filing  
7/1/2013Juergen LasowskiEVPSell25,375$132.63$3,365,486.25View SEC Filing  
7/1/2013Julianna R WoodVPSell2,304$132.63$305,579.52View SEC Filing  
7/1/2013Paul GoddardDirectorSell6,000$132.21$793,260.00View SEC Filing  
6/19/2013Corinne H NevinnyDirectorSell1,000$88.25$88,250.00View SEC Filing  
6/10/2013Julianna R WoodVPSell2,306$92.30$212,843.80View SEC Filing  
6/7/2013Suzanne M ShemaEVPSell4,052$91.23$369,663.96View SEC Filing  
6/5/2013N Anthony ColesCEOSell6,562$90.00$590,580.00View SEC Filing  
5/14/2013Juergen LasowskiEVPSell4,182$96.60$403,981.20View SEC Filing  
5/13/2013Helen TorleyEVPSell8,250$98.13$809,572.50View SEC Filing  
5/13/2013Matthew K FustCFOSell10,269$98.22$1,008,621.18View SEC Filing  
4/11/2013Lopez Antonio J GrilloDirectorSell43,164$96.73$4,175,253.72View SEC Filing  
4/10/2013Julianna R WoodVPSell9,948$95.00$945,060.00View SEC Filing  
4/10/2013Paul GoddardDirectorSell2,000$95.00$190,000.00View SEC Filing  
3/11/2013Julianna R WoodVPSell3,331$85.65$285,300.15View SEC Filing  
3/11/2013Magnus LundbergDirectorSell5,000$88.00$440,000.00View SEC Filing  
10/5/2012Juergen LasowskiEVPSell5,902$90.00$531,180.00View SEC Filing  
10/4/2012Helen TorleyEVPSell2,314$86.51$200,184.14View SEC Filing  
10/2/2012Kaye I Foster-CheekSVPSell2,015$85.08$171,436.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Onyx Pharmaceuticals (NASDAQ ONXX) News Headlines

Source:
DateHeadline
Google unit stakes biotech claim with lease of entire Onyx campusGoogle unit stakes biotech claim with lease of entire Onyx campus
www.bizjournals.com - February 18 at 9:31 AM
Former Teva CEOs new gig at Ovid TherapeuticsFormer Teva CEO's new gig at Ovid Therapeutics
www.cnbc.com - April 16 at 6:10 AM

SEC Filings

Onyx Pharmaceuticals (NASDAQ:ONXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Onyx Pharmaceuticals (NASDAQ:ONXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Onyx Pharmaceuticals (NASDAQ ONXX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.